A selective inhibitor of COX-2
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Lumiracoxib

Item No. 27645

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
2-[(2-chloro-6-fluorophenyl)amino]-5-methyl-benzeneacetic acid
CAS Number
220991-20-8
Synonyms
  • COX 189
Molecular Formula
C15H13ClFNO2
Formula Weight
293.7
Purity
≥98%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMSO: 30 mg/mlDMSO:PBS (pH 7.2) (1:4): 0.20 mg/ml
λmax
274 nm
SMILES
CC1=CC(CC(O)=O)=C(NC2=C(Cl)C=CC=C2F)C=C1
InChi Code
InChI=1S/C15H13ClFNO2/c1-9-5-6-13(10(7-9)8-14(19)20)18-15-11(16)3-2-4-12(15)17/h2-7,18H,8H2,1H3,(H,19,20)
InChi Key
KHPKQFYUPIUARC-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    10 mg

    $36

    Add

    50 mg

    $95

    Add

    100 mg

    $169

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Lumiracoxib is a selective inhibitor of COX-2 with IC50 values of 0.13 and 67 µM for COX-2 and COX-1, respectively, in isolated human whole blood.1 It reduces increases in the levels of prostaglandin E2 (PGE2; Item No. 14010) induced by IL-1β in human dermal fibroblasts (IC50 = 0.14 µM), as well as in LPS-stimulated RAW 264.7 cells when used at concentrations ranging from 1 to 100 µM.1,2 Lumiracoxib (3 and 10 mg/kg) also decreases LPS-induced increases in the levels of PGE2 in a rat model of air pouch inflammation.3 It reduces M. tuberculosis-induced increases in hind paw volume and the radiological and histopathological severity of arthritic lesions in a rat model of chronic arthritis when administered at a dose of 2 mg/kg.1

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Esser, R., Berry, C., Du, Z., et al. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br. J. Pharmacol. 144(4), 538-550 (2005).

    2. Niederberger, E., Manderscheid, C., and Geisslinger, G. Different COX-independent effects of the COX-2 inhibitors etoricoxib and lumiracoxib. Biochem. Biophys. Res. Commun. 342(3), 940-948 (2006).

    3. Esser, R.E., Miserendino-Molteni, R., Sharr, M., et al. Pharmacodynamic behaviour of the selective cyclooxygenase-2 inhibitor lumiracoxib in the lipopolysaccharide-stimulated rat air pouch model. Eur. J. Pharm. Sci. 25(1), 25-30 (2005).